Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This micro-cap stock is leading the US graphite revolution (click to learn more) Eric Sprott Announces Changes to His Holdings in Honey Badger Silver Inc. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News XTL Biopharmaceuticals Ltd XTLB

Healthcare Biotechnology
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company... see more

Recent & Breaking News (NDAQ:XTLB)

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

GlobeNewswire April 29, 2026

XTL Biopharmaceuticals Announces ADS Ratio Change

GlobeNewswire March 20, 2026

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

GlobeNewswire February 27, 2026

XTL Update on Recent Developments

GlobeNewswire January 29, 2026

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

GlobeNewswire January 23, 2026

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

GlobeNewswire January 13, 2026

XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

GlobeNewswire January 13, 2026

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

GlobeNewswire December 24, 2025

XTL Names Mr. Noam Band as its New Chief Executive Officer

GlobeNewswire April 7, 2025

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

GlobeNewswire August 14, 2024

XTL Entered Definitive Agreement to Acquire The Social Proxy

GlobeNewswire June 5, 2024

XTL To Aquire The Social Proxy

GlobeNewswire March 20, 2024

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire October 20, 2023

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

GlobeNewswire October 20, 2023

Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 21, 2018

XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update

PR Newswire November 1, 2018

XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update

PR Newswire July 24, 2018

XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update

PR Newswire May 29, 2018

26 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  May 16, 2018

XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

PR Newswire December 6, 2017

Podcasts